{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:24:19Z","timestamp":1765484659483},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2001,5]]},"DOI":"10.1006\/cyto.2001.0877","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T15:45:48Z","timestamp":1032191148000},"page":"218-224","source":"Crossref","is-referenced-by-count":19,"title":["INTERLEUKIN 1 COMPONENTS IN CICATRICIAL PEMPHIGOID. ROLE IN INTRAVENOUS IMMUNOGLOBULIN THERAPY"],"prefix":"10.1006","volume":"14","author":[{"given":"Suman","family":"Kumari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailash C.","family":"Bhol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.Razzaque","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/cyto.2001.0877_RF1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-4362.1986.tb04544.x","article-title":"Cicatricial pemphigoid","volume":"25","author":"Ahmed","year":"1986","journal-title":"Int J Dermatol"},{"key":"10.1006\/cyto.2001.0877_RF2","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1006\/cyto.2001.0877_RF3","series-title":"Dermatology in General Medicine","first-page":"606","article-title":"Bullous pemphigoid, cicatricial pemphigoid, and chronic bullous disease of childhood","author":"Stanley","year":"1993"},{"key":"10.1006\/cyto.2001.0877_RF4","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/S0161-6420(99)90496-7","article-title":"Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid","volume":"106","author":"Foster","year":"1999","journal-title":"Ophthalmol"},{"key":"10.1006\/cyto.2001.0877_RF5","first-page":"119","article-title":"Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders","volume":"74","author":"Mobini","year":"1995","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1006\/cyto.2001.0877_RF6","first-page":"95","article-title":"Different modes of action of high-dose immunoglobulins in rheumatoid arthritis","volume":"40","author":"Delire","year":"1994","journal-title":"Acta Univ Carol"},{"key":"10.1006\/cyto.2001.0877_RF7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM198608073150601","article-title":"The treatment of kawasaki syndrome with intravenous gamma globulin","volume":"315","author":"Newburger","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1006\/cyto.2001.0877_RF8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","article-title":"Intravenous immune globulin therapy for neurologic disease","volume":"126","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1006\/cyto.2001.0877_RF9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1006\/cyto.2001.0877_RF10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.57.Suppl.6","article-title":"Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases","volume":"57","author":"Kaveri","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1006\/cyto.2001.0877_RF11","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/0090-1229(92)90044-O","article-title":"Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune\/idiotype network","volume":"62","author":"Dietrich","year":"1992","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1006\/cyto.2001.0877_RF12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cei.1996.104.s1.3","article-title":"Mechanisms of action of intravenous immune globulin in immune mediated diseases","volume":"104","author":"Mouthon","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1006\/cyto.2001.0877_RF13","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood.V84.7.2136.2136","article-title":"Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo","volume":"84","author":"Aukrust","year":"1994","journal-title":"Blood"},{"key":"10.1006\/cyto.2001.0877_RF14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1994.tb00854.x","article-title":"Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy","volume":"139","author":"Abe","year":"1994","journal-title":"Immunol Rev"},{"key":"10.1006\/cyto.2001.0877_RF15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/clin.1994.1027","article-title":"Lymphokines in autoimmunity-a critical review","volume":"70","author":"Schattner","year":"1994","journal-title":"Clin Immunol immunopathol"},{"key":"10.1006\/cyto.2001.0877_RF16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/ard.54.5.382","article-title":"Long term treatment of rheumatoid arthritis with high-doses of intravenous immunoglobulins: effects on disease activity and serum cytokines","volume":"54","author":"Muscat","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1006\/cyto.2001.0877_RF17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF02002715","article-title":"Effects of immunoglobulin and gamma-interferon on the production of tumor necrosis factor-alpha and interleukin-1beta by peripheral blood monocytes in the acute phase of kawasaki disease","volume":"155","author":"Suzuki","year":"1996","journal-title":"Eur J Pediatr"},{"key":"10.1006\/cyto.2001.0877_RF18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF02870186","article-title":"Interleukin-1alpha (IL-1alpha), IL-1beta, IL-1receptor type I, IL-1receptor antagonist, and TGF-beta1 mRNAs in pediatrics astrocytomas ependymomas, and primitive neurectodermal tumors","volume":"33","author":"Ilyin","year":"1998","journal-title":"Mol Chem Neuropathol"},{"key":"10.1006\/cyto.2001.0877_RF19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1096\/fasebj.2.2.3277884","article-title":"Biology of interleukin-1","volume":"2","author":"Dinarello","year":"1988","journal-title":"FASEB J"},{"key":"10.1006\/cyto.2001.0877_RF20","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood.V77.8.1627.1627","article-title":"Interleukin-1 and interleukin-1 antagonism","volume":"77","author":"Dinarello","year":"1991","journal-title":"Blood"},{"key":"10.1006\/cyto.2001.0877_RF21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/344633a0","article-title":"Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein","volume":"344","author":"Carter","year":"1990","journal-title":"Nature"},{"key":"10.1006\/cyto.2001.0877_RF22","first-page":"365","article-title":"Inhibiting the effects of cytokines in human diseases","volume":"40","author":"Arend","year":"1995","journal-title":"Adv Intern Med"},{"key":"10.1006\/cyto.2001.0877_RF23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/stem.5530130303","article-title":"Cytokines and autoantibodies to cytokines","volume":"13","author":"Bendtzen","year":"1995","journal-title":"Stem Cells"},{"key":"10.1006\/cyto.2001.0877_RF24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/1529-0131(199806)41:6<1083::AID-ART15>3.0.CO;2-9","article-title":"Elevated levels of soluble interleukin-1 receptor type II and its interleukin-1 receptor antagonist in patients with chronic arthritis: correlation with markers of inflammation and joint destruction","volume":"41","author":"Jouvenne","year":"1998","journal-title":"Arthritis Rheumatol"},{"key":"10.1006\/cyto.2001.0877_RF25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/00365529850171891","article-title":"Detection of pro- and anti-inflammatory cytokines in stool of patients with inflammatory bowel disease","volume":"33","author":"Saiki","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"10.1006\/cyto.2001.0877_RF26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/WNL.52.3.595","article-title":"Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS","volume":"52","author":"Schrijver","year":"1999","journal-title":"Neurology"},{"key":"10.1006\/cyto.2001.0877_RF27","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(87)90494-6","article-title":"High-dose versus low dose intravenous gammaglobulin in hypoglobulinemia and chronic lung disease","volume":"1","author":"Roifman","year":"1987","journal-title":"Lancet"},{"key":"10.1006\/cyto.2001.0877_RF28","first-page":"3522","article-title":"Serum levels of tumor Necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid","volume":"34","author":"Lee","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1006\/cyto.2001.0877_RF29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.iy.06.040188.002255","article-title":"Regulation of cytokine gene expression","volume":"6","author":"Taniguchi","year":"1988","journal-title":"Annu Rev Immunol"},{"key":"10.1006\/cyto.2001.0877_RF30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002689900401","article-title":"Cytokines in inflammatory bowel disease","volume":"22","author":"Rogler","year":"1998","journal-title":"World J Surg"},{"key":"10.1006\/cyto.2001.0877_RF31","first-page":"675","article-title":"The interleukin-1 and interlekin-1 converting enzyme families in the cardiovascular system","volume":"9","author":"Lappnow","year":"1998","journal-title":"Eur Cyto Network"},{"key":"10.1006\/cyto.2001.0877_RF32","doi-asserted-by":"crossref","first-page":"71412","DOI":"10.1016\/S0041-1345(98)02109-5","article-title":"Interleukin-1beta induces endothelin-1 gene by multiple mechanisms","volume":"31","author":"Herman","year":"1999","journal-title":"Transplant Proc"},{"key":"10.1006\/cyto.2001.0877_RF33","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A","article-title":"Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal model of arthritis. Comparison of efficacy in animal model with human clinical data","volume":"42","author":"Bendele","year":"1999","journal-title":"Arthri Rheumatol"},{"key":"10.1006\/cyto.2001.0877_RF34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0099-2399(98)80089-7","article-title":"Balance of interleukin-1 beta and interleukin-1 receptor antagonist in human periapical lesions","volume":"24","author":"Shimauchi","year":"1998","journal-title":"J Endod"},{"key":"10.1006\/cyto.2001.0877_RF35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/08916939908993804","article-title":"Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE","volume":"30","author":"Andersen","year":"1999","journal-title":"Autoimmunity"},{"key":"10.1006\/cyto.2001.0877_RF36","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1006\/cyto.2001.0877_RF37","first-page":"211","article-title":"Down regulation of cytokine production and interleukin-2 receptor expression by pooled IgG","volume":"79","author":"Andersson","year":"1993","journal-title":"Immunology"},{"key":"10.1006\/cyto.2001.0877_RF38","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/eji.1830240420","article-title":"Lymphokine production induced by streptococcal pyrogenicexotoxin-A is selectively down-regulated by pooled human IgG","volume":"24","author":"Skansen-Saphir","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1006\/cyto.2001.0877_RF39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","article-title":"Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies","volume":"10","author":"Brattsand","year":"1996","journal-title":"Ailment Pharmacol Ther"},{"key":"10.1006\/cyto.2001.0877_RF40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0753-3322(90)90172-6","article-title":"Effect of dexamethasone on IL-1 and IL-3LA release by unstimulated human mononuclear cells","volume":"44","author":"Djaldetti","year":"1990","journal-title":"Biomed Pharmacol Ther"},{"key":"10.1006\/cyto.2001.0877_RF41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0162-3109(94)90013-2","article-title":"Effects of corticosteroids, cyclosporin A, and methotrexate on cytokine release from monocytes and T-cell subsets","volume":"27","author":"Schmidt","year":"1994","journal-title":"Immunopharmacol"},{"key":"10.1006\/cyto.2001.0877_RF42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cei.1996.104.s1.10","article-title":"Intravenous immune globulin affects cytokine production in lymphocytes and monocytes\/macrophages","volume":"104","author":"Andersson","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1006\/cyto.2001.0877_RF43","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood.V90.6.2376","article-title":"Increased in-vivo antibody activity against interferon-alpha, interleukin-alpha and interleukin-6 after high dose Ig therapy","volume":"90","author":"Ross","year":"1997","journal-title":"Blood"},{"key":"10.1006\/cyto.2001.0877_RF44","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/eji.1830250521","article-title":"Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)","volume":"25","author":"Ruiz de Souza","year":"1995","journal-title":"Eur J Immunol"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466601908774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466601908774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T15:21:02Z","timestamp":1576509662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466601908774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["S1043466601908774"],"URL":"https:\/\/doi.org\/10.1006\/cyto.2001.0877","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}